174 related articles for article (PubMed ID: 32789649)
21. Prognostic value of baseline metabolic tumor volume measured on
Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098
[TBL] [Abstract][Full Text] [Related]
22. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.
Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA
Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852
[TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
24. Influence of volumetric 4'-[methyl-
Hoshikawa H; Mori T; Maeda Y; Takahashi S; Ouchi Y; Yamamoto Y; Nishiyama Y
Ann Nucl Med; 2017 Jan; 31(1):63-70. PubMed ID: 27679399
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
[TBL] [Abstract][Full Text] [Related]
26. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
Iagaru A; Quon A; McDougall IR; Gambhir SS
Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
[TBL] [Abstract][Full Text] [Related]
27. Pre-Therapeutic Total Lesion Glycolysis on [
Mayerhoefer ME; Staudenherz A; Kiesewetter B; Weber M; Simonitsch-Klupp I; Gibbs P; Dolak W; Lukas J; Raderer M
Mol Imaging Biol; 2019 Dec; 21(6):1192-1199. PubMed ID: 30847823
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
31. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
32. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
[TBL] [Abstract][Full Text] [Related]
33. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
34. Use of FDG PET/CT in Patients with Pancoast Tumors: Does It Add Any Contribution to Patient Management?
Ozmen O; Yilmaz U; Dadali Y; Tatci E; Gokcek A; Aydin E; Okuyucu K; Arslan N
Cancer Biother Radiopharm; 2015 Oct; 30(8):359-67. PubMed ID: 26367245
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of
Shao D; Gao Q; Cheng Y; Du DY; Wang SY; Wang SX
Korean J Radiol; 2021 Mar; 22(3):425-434. PubMed ID: 33236543
[TBL] [Abstract][Full Text] [Related]
36. The value of different
Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
38.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
39. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
[TBL] [Abstract][Full Text] [Related]
40. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
